je.st
news
Tag: insulin
Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
2013-03-28 09:57:29| dairynetwork Home Page
Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.
Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
2013-03-28 09:57:29| dairynetwork News Articles
Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.
Study Suggests High Dietary Fiber Related to Low Levels of Insulin Resistance in Women
2013-02-27 09:00:59| Food Processing
Consumers can add insulin resistance as an increasingly important concern along with obesity and type 2 diabetes; however, food processors can add fiber and resistant starch in tasty, functional foods and beverages to help counter that concern.
Oramed Pharmaceuticals Moves Forward With Investigational New Drug Application For Oral Insulin
2013-02-27 01:19:04| drugdiscoveryonline News Articles
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin
Tags: application
forward
drug
oral
Oramed Pharmaceuticals Moves Forward With Investigational New Drug Application For Oral Insulin
2013-02-27 01:19:04| drugdiscoveryonline Home Page
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin
Tags: application
forward
drug
oral